INDP: Indaptus Therapeutics, Inc. Company Aggregate Debts

Indaptus Therapeutics (INDP) is executing its research and development programs as scheduled, supported by precision equipment. The price trajectory shown below correlates with the 0.00 metric. The business relies on outsourcing drug synthesis and testing to external contractors, creating a dependency on third-party quotas. The company's success is based on the efficacy of bacterial vectors in treating tumors, patent protection, and the ability to attract R&D investment.

An analysis of the funds raised by Indaptus Therapeutics (INDP) with a value of 0.00 reflects the total volume of debt obligations, determining the business's degree of dependence on external borrowing and its overall solvency. For a company investing in a staff of leading biochemists and compliance experts, this metric serves as an indicator of financial stability during the implementation of costly clinical trials for anti-tumor drugs.